CERENOME, INC. cotiza a 1.81 USD y tiene una capitalización bursátil de $14M. En los últimos 12 meses ha facturado $4M con un margen de flujo de caja libre del -399.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, includi…
| Periodo | 2026-05 | 2026-03 | 2025-10 | 2025-08 |
|---|---|---|---|---|
| Real | $-1.05 | — | $-1.00 | $-0.16 |
| Estimado | $-0.87 | $-0.92 | $-0.87 | $-3.25 |
| Sorpresa | -20.7% | — | -14.9% | +95.1% |
| Métrica | CNSY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -293.5% | -38.6% | -254.8% |
| Net Margin | -429.4% | -33.6% | -395.9% |
| FCF Margin | -399.8% | -13.9% | -385.9% |
| ROE | -560.2% | -40.4% | -519.8% |
| ROA | -137.1% | -32.0% | -105.1% |
| Current Ratio | 1.23 | 2.84 | -1.61 |
| Debt / Equity | — | 0.28 | — |